POP1 Drug Discovery Program Advanced by Propanc Biopharma

Propanc Biopharma, Inc., a biopharmaceutical company creating new cancer therapies for patients with recurrent and metastatic cancer, today reported that the POP1 study and drug discovery program has made great progress in the creation of synthetic variants of both proenzymes, trypsinogen, and chymotrypsinogen. The Organization is conducting a complex research study in partnership with both the universities of Jaén and Granada, headed b....